With our phage being temperate, as of now, I don’t think our phage would be a good candidate. There is less known about the use of phage therapy with temperate phage. Lytic phage are currently the star candidate for phage therapy tests and studies as it lyses/kills the bacterial infection in a direct rapid way. While temperate phage integrate into the bacterial host genome, it can be more complex and less predictable then lytic phage (infecting and lysing the cell rather quickly).
The different tail lengths of the phage are crucial in phage infection. Phage present themselves as a few different families, however we mainly focused on myoviridae and siphoviridae. Siphoviridae have longer, flexible tails that could make it more difficult for the phage to attach to and inject its genome into the host cell. Myoviridae phage have shorter, contractile tails that can puncture the bacterial cell wall and infect the host that is often more effective and rapid in its infecting. Myoviridae phage would be a bit better at infecting the bacterial host so that would be a more ideal candidate for phage therapy.
Considering the possibility that your phage can be used as a phage therapy, would it be beneficial to fund and produce this phage as a beneficial treatment? Or are the B1 infections not profitable to pursue treatment development?
Our individual phage wouldn’t be an ideal candidate as it is a temperate phage. However phage found in the B1 cluster have been studied and found that B1 infects Bacillus cereus which is a common soil bacterium that can cause food poisoning and staphylococcus aureus which is a common skin infection in humans. So phage in the B1 cluster family have been successful in fighting against harmful bacteria therefore B1 infections could be profitable to pursue in the treatment of phage therapy.
The main phage families other then siphoviridae are podoviridae and myoviridae. Myoviridae have a larger head and shorter tail than siphoviridae. Myoviridae also have contractile tails while siphoviridae do not. Podoviridae phage have even shorter, non flexible tails. These phage are typically much smaller then both siphoviridae and myoviridae.
After running this experiment, do you think your phage could be a good candidate for phage therapy?
With our phage being temperate, as of now, I don’t think our phage would be a good candidate. There is less known about the use of phage therapy with temperate phage. Lytic phage are currently the star candidate for phage therapy tests and studies as it lyses/kills the bacterial infection in a direct rapid way. While temperate phage integrate into the bacterial host genome, it can be more complex and less predictable then lytic phage (infecting and lysing the cell rather quickly).
You mentioned the different tail lengths on the phage. Do they effect how good of a candidate the phage will be?
The different tail lengths of the phage are crucial in phage infection. Phage present themselves as a few different families, however we mainly focused on myoviridae and siphoviridae. Siphoviridae have longer, flexible tails that could make it more difficult for the phage to attach to and inject its genome into the host cell. Myoviridae phage have shorter, contractile tails that can puncture the bacterial cell wall and infect the host that is often more effective and rapid in its infecting. Myoviridae phage would be a bit better at infecting the bacterial host so that would be a more ideal candidate for phage therapy.
Considering the possibility that your phage can be used as a phage therapy, would it be beneficial to fund and produce this phage as a beneficial treatment? Or are the B1 infections not profitable to pursue treatment development?
Our individual phage wouldn’t be an ideal candidate as it is a temperate phage. However phage found in the B1 cluster have been studied and found that B1 infects Bacillus cereus which is a common soil bacterium that can cause food poisoning and staphylococcus aureus which is a common skin infection in humans. So phage in the B1 cluster family have been successful in fighting against harmful bacteria therefore B1 infections could be profitable to pursue in the treatment of phage therapy.
What are the types of phage other than Siphoviridae, and how would those look different from the Siphoviridae?
The main phage families other then siphoviridae are podoviridae and myoviridae. Myoviridae have a larger head and shorter tail than siphoviridae. Myoviridae also have contractile tails while siphoviridae do not. Podoviridae phage have even shorter, non flexible tails. These phage are typically much smaller then both siphoviridae and myoviridae.